Login to Your Account

"Casting a wide net" with its phase I trial testing MRX34, Mirna Therapeutics Inc. raked in $41.8 million by way of a series D financing that will enable a phase II experiment in the first half of next year, in a cancer indication yet to be decided upon, CEO Paul Lammers told BioWorld Today.

Sanbio Co. Ltd., a small trans-Pacific cell therapy company leveraging Japan's efforts to foster regenerative medicine development, has completed an IPO of shares (TYO:4592) on the Tokyo Stock Exchange to help it advance SB623, its lead mesenchymal stem cell-based treatment for chronic stroke.

Royalty investors backing a matchstick-sized implantable drug pump in late-stage testing by Intarcia Therapeutics Inc. invested $225 million in the company to carry the first version of the device through potential approval and early launch in 2017.

More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: